Novo Nordisk has reported that its oral semaglutide medicine showed non-inferiority compared to...
MyoKardia starts dosing hypertrophic cardiomyopathy patients
MyoKardia has commenced dosing of patients in a Phase I trial of small molecule MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM).
Farxiga meets primary goal in Phase III heart failure trial
AstraZeneca’s Farxiga (dapagliflozin) has met the primary endpoint in Phase III DAPA-HF study involving patients with reduced ejection fraction (HFrEF), with or without type 2 diabetes.
Medable to enhance digital real-world evidence research network
US-based data-driven clinical trials provider Medable is set to join the American Heart Association’s Center for Health Technology & Innovation Innovators Network to improve a patient-centric digital system that connects patients and researchers.
Biofourmis partners with Yale University for heart failure research
Biofourmis has signed a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI).
Trial shows cardiovascular safety with Novo Nordisk’s diabetes drug
Novo Nordisk has reported that its oral semaglutide medicine showed non-inferiority compared to placebo in major adverse cardiovascular events (MACE) during the PIONEER 6 clinical trial in type 2 diabetes patients.
Expert Insights: Moderna Therapeutics Barrels Ahead Towards Historic IPO
Paul Jeng, PhD, Infectious Diseases Analyst, GlobalData, analyzes Moderna Therapeutics’ growing stature as the young biotech punches above its weight
Cardax doses first patient in CHASE trial for cardiovascular health drug
Cardax has dosed the first patient in its Cardiovascular Health Astaxanthin Supplement Evaluation (CHASE) clinical trial that aims to investigate the effect of ZanthoSyn for the treatment of cardiovascular inflammatory health.
Lokelma (sodium zirconium cyclosilicate) for the Treatment of Adults with Hyperkalaemia
Lokelma is an oral suspension of sodium zirconium cyclosilicate that is indicated for the treatment of patients with hyperkalaemia.